BRAF and neoplasm: A further important observation from mouse models and human CRC is that mutations activating KRAS and BRAF do not necessarily result in tumor formation in the intestinal epithelium, due to the existence of fail-safe mechanisms suppressing tumor growth after MAPK activation.